EXPERT VIEW: Recent Cases Lift Pharma Confidence In India IP Protection
This article was originally published in PharmAsia News
Executive Summary
Dr. Jonathan Atkinson, member of the board of HGF Ltd, the UK-based intellectual property law firm, has seen a steady pick-up in confidence in India's intellectual property rights (IPR) regime amid a string of critical judgments concerning Big Pharma over the recent past.
You may also be interested in...
AstraZeneca Bolstering India Play With $90m Investment Plan
AstraZeneca expects to invest $90m over five years to shore up its footprint in India – a market where the Anglo-Swedish major has introduced a string of new products but has also had a fair share of challenges.
Indian Firms Push For Favorable USTR IPR Review
It’s that time of the year when Indian and US firms lock horns around all things IPR [intellectual property rights] ahead of the USTR’s annual Special 301 report. Indian pharma firms want India off the USTR’s Priority Watch List, while PhRMA says it remains concerned about the challenging policy environment and weak patent enforcement in India.
Onward Ho: Biocon Signals Glargine Build Up, US Biosimilars Pricing ‘Sanity’
Biocon anticipates significant US uptake of its Viatris-partnered interchangeable insulin glargine biosimilar on the back of commercial arrangements in place and expects to "move the market" in 2022. All eyes are also on the trajectory of biosimilar insulin aspart, which received a CRL from the US FDA.